This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Alnylam Pharmaceuticals Inc (ALNY)

NASDAQ: Health Care

Company Balance Sheet
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Assets
Cash and Equivalents 53.17M 51.40M 70.23M 74.60M
Receivables 4.25M 104.00K 1.47M 14.12M
Inventories 0.00 0.00 0.00 0.00
Other Current Assets 0.00 0.00 0.00 0.00
Total Current Assets 254.03M 125.46M 152.03M 254.14M
Property, Plant & Equipment, Gross 57.76M 55.27M 45.57M 44.63M
Accumulated Depreciation & Depletion 41.32M 35.47M 30.92M 26.34M
Property, Plant & Equipment, Net 16.45M 19.80M 14.64M 18.29M
Intangibles 0.00 0.00 275.00K 448.00K
Other Non-Current Assets 150.05M 142.26M 114.97M 120.39M
Total Non-Current Assets 166.50M 162.06M 129.89M 139.13M
Liabilities & Shareholder Equity
Total Assets 420.53M 287.52M 281.92M 393.26M
Accounts Payable 5.90M 4.42M 5.80M 9.31M
Short Term Debt 0.00 0.00 0.00 0.00
Other Current Liabilities 1.11M 0.00 484.00K 0.00
Total Current Liabilities 53.86M 48.34M 80.99M 102.05M
Long Term Debt 0.00 0.00 0.00 0.00
Deferred Income Taxes 2.92M 0.00 3.73M 2.87M
Other Non-Current Liabilities 93.39M 105.12M 79.20M 130.12M
Minority Interest 0.00 0.00 0.00 0.00
Total Non-Current Liabilities 96.32M 105.12M 82.93M 132.99M
Total Liabilities 150.18M 153.47M 163.92M 235.03M
Preferred Stock Equity 0.00 0.00 0.00 0.00
Common Stock Equity 270.35M 134.05M 118.00M 158.23M
Common Par 637.00K 525.00K 427.00K 423.00K
Additional Paid In Capital 846.23M 624.88M 518.73M 500.44M
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings -596.24M -507.01M -401.00M -343.35M
Treasury Stock 0.00 0.00 0.00 0.00
Other Equity Adjustments 19.72M 15.66M -165.00K 714.00K
Total Capitalization 270.35M 134.05M 118.00M 158.23M
Total Equity 270.35M 134.05M 118.00M 158.23M
Total Liabilities & Stock Equity 420.53M 287.52M 281.92M 393.26M
Total Common Shares Outstanding 63.74M 52.49M 42.72M 42.34M
Preferred Shares 0.00 0.00 0.00 0.00
Treasury Shares 0.00 0.00 0.00 0.00
Basic Weighted Shares Outstanding 61.55M 50.29M 42.41M 42.04M
Diluted Weighted Shares Outstanding 61.55M 50.29M 42.41M 42.04M
Number of Employees 165 129 116 172
Number of Part-Time Employees 0 0 0 0
ALNY News

ALNY Alnylam Pharmaceuticals Inc

Analysts Ratings for ALNY

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 3 4 3
Moderate Buy 1 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET ALNY ANALYST REPORT

Brokerage Partners

ALNY Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs